Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hyperPET for Metabolic Imaging in Patients With Cancer
NCT05396118Phase 2Enrolling by invitation
- Sponsor
- Rigshospitalet
- Start
- May 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fludeoxyglucose f 18, [1-13C]pyruvate in breast cancer, Neuroendocrine Neoplasm (NEN), lymphoma, sarcoma, sponsored by Rigshospitalet. Started May 2022; status: enrolling by invitation.
02
Drugs
fludeoxyglucose f 18[1-13C]pyruvate
03
Conditions
breast cancerNeuroendocrine Neoplasm (NEN)lymphomasarcoma
Beyond the preview
Go deeper on NCT05396118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396118.